Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
An announcement from Abeona Therapeutics ( (ABEO) ) is now available.
On May 19, 2025, Abeona Therapeutics Inc. held its annual stockholders’ meeting virtually. During the meeting, Mark J. Alvino, Faith L. Charles, and Donald A. Wuchterl were elected as Class 3 directors to serve until the 2028 meeting. Additionally, stockholders approved the compensation of named executive officers and ratified Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (ABEO) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Abeona Therapeutics stock, see the ABEO Stock Forecast page.
Spark’s Take on ABEO Stock
According to Spark, TipRanks’ AI Analyst, ABEO is a Neutral.
Abeona Therapeutics faces substantial financial challenges with no current revenue and ongoing losses, impacting its overall score. However, the promising potential for FDA approvals and significant revenue opportunities from new therapies provide a positive outlook. Despite bullish technical signals, the high RSI suggests caution. The stock’s valuation remains unattractive due to its negative P/E ratio, but strong earnings call projections and adequate cash reserves offer some optimism for future performance.
To see Spark’s full report on ABEO stock, click here.
More about Abeona Therapeutics
Average Trading Volume: 1,495,075
Technical Sentiment Signal: Hold
Current Market Cap: $312.1M
Find detailed analytics on ABEO stock on TipRanks’ Stock Analysis page.